CI The Cigna Group - Fundamental Analysis

NEUTRAL

CI Stock | Fundamental Analysis & Investment Insights

NYSE • Healthcare • Healthcare Plans

Current Price Live

$272.21

Analyst Target

$326.92

+20.1% Upside

52W High

$350.0

52W Low

$239.51

Overview AI Snowflake Price Valuation More metrics Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Unlock key metrics

Market cap, P/E, ROE, margins, leverage and more.

AI Analysis

Confidence Score

72%

Analysis Accuracy

The Cigna Group (CI) exhibits a weak Piotroski F-Score of 4/9, indicating marginal financial health, and lacks an Altman Z-Score, limiting distress risk assessment. Despite this, the stock appears attractively valued with a P/E of 12.04 and forward P/E of 8.94, well below sector averages, while trading below the Graham Number of $282.38. Strong earnings growth of 165.4% YoY and solid ROE of 15.54% support momentum, but bearish insider activity and weak technical trend (0/100) counterbalance optimism. Analysts recommend a 'buy' with a target price of $326.92, implying 20% upside.

Key Strengths

Attractive valuation metrics: P/E of 12.04 and forward P/E of 8.94 significantly below sector average of 249.64

Strong year-over-year earnings growth of 165.4% and Q/Q EPS growth of 8.7%

High return on equity (ROE) of 15.54%, above cost of capital and indicative of efficient equity use

Low payout ratio of 26.25% provides dividend sustainability and reinvestment capacity

Trading below Graham Number ($282.38) at current price of $272.21, suggesting undervaluation

Key Risks

Weak Piotroski F-Score of 4/9 indicates suboptimal financial stability and mixed profitability signals

Current ratio of 0.83 and quick ratio of 0.69 suggest potential liquidity pressure in the short term

Bearish technical trend (0/100) and declining price performance over 6M (-7.0%) and 1Y (-1.1%)

Insider selling activity: $10.17M in sales over last 6 months with no buys, signaling lack of confidence

Missing key financial data (EV, cash, debt, ROIC, free cash flow) limits comprehensive health assessment

AI Fair Value Estimate

Based on comprehensive analysis

$282.38

+3.7% above current price

Performance Snowflake

Multi-dimensional AI analysis across 5 key categories

Unlock AI-Powered Analysis

See Value, Future Performance, Past Performance, Financial Health & Dividend scores

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Unlock Price Charts

View historical price trends and analyst targets

Historical Performance Trends

Long-term financial metrics and growth patterns

Unlock Historical Data

View 3-year revenue, profit margins, and growth trends

Valuation Metrics

Key valuation ratios and pricing indicators

P/E, P/B, P/S, EV/EBITDA and more

Profitability, Growth & Financial Health

Detailed profit margins, ROE, debt ratios, and liquidity metrics

Unlock Detailed Metrics

View ROE, Operating Margin, Debt/Equity, Current Ratio and more

Sector Comparison & Peer Analysis

Compare CI against industry averages and similar companies

Unlock Sector Insights

See how CI compares to competitors and industry standards

Insider Trading & Analyst Ratings

Track insider transactions and Wall Street analyst recommendations

Unlock Insider Data

See recent insider buys/sells and analyst price targets

Past News Coverage

Recent headlines mentioning CI from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V1 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends